Could buying this gene-editing penny stock at $1 make me rich?
This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.
Genome-edited stem cells reveal new hope for obesity treatment without muscle loss
In a study published in Nature Communications, researchers at the Beijing Institute of Stem Cells and Regeneration (BISCRM) ...
The Tech Edvocate2d
Top 100 Biotech Companies Revolutionizing Healthcare in 2025
Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...
Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight
The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the demand for gene therapy and genome editing solutions, as these approaches ...
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
On track to declare two in vivo editingdevelopment candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present ...
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...